Original Articles and Brief Reports

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA
Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP) and Paris 13 Université, Bobigny, France
AOU Careggi, University of Florence, Italy
James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
Mount Sinai School of Medicine, New York, NY, USA
Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia
Karolinska University Hospital, Stockholm, Sweden
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Moffitt Cancer Center, Tampa, FL, USA
Vol. 98 No. 7 (2013): July, 2013 https://doi.org/10.3324/haematol.2012.074831